The scientific foundation of iPremom

iPremom develops prenatal diagnostic solutions based on the identification of early molecular alterations associated with pregnancy complications. Our approach integrates:

  • Endometrial and placental biology
  • Transcriptomic analysis
  • Multi-omics technologies
  • Liquid biopsy (cfRNA)
  • Predictive models based on artificial intelligence

The aim is to detect biological alterations before the appearance of clinical symptoms, allowing for early intervention.

The biological origin of preeclampsia

Our research has identified a key mechanism in the development of preeclampsia:

This process is associated with:

These alterations generate a molecular signature detectable in maternal blood through cfRNA.

An approach centred on the uterus

Our research has identified a key mechanism in the development of preeclampsia:

01 — Decidualisation

Decidualisation prepares the uterus for embryonic invasion and placental development. We have demonstrated the maternal contribution to severe preeclampsia through defective decidualisation.

02 — Placentation

The placenta provides nutrients and oxygen to the embryo. Defective decidualisation alters maternal-fetal communication during placentation.

03 — Molecular signal

cfRNA molecules reflect dynamic changes in the biology of pregnancy. Our technology makes it possible to detect these signals and predict complications before the appearance of symptoms.

Technological approach

iPremom's technology is based on an integrated pipeline:

Liquid biopsy

Extraction of circulating cell-free RNA (cfRNA) from maternal plasma

Molecular processing

Library preparation
Sequencing using NGS (Next-Generation Sequencing)
Quality control

Bioinformatic analysis

Processing of transcriptomic data
Integration of clinical variables

Predictive model

Algorithm based on artificial intelligence
Generation of an individualised preeclampsia risk during the first trimester

iPremom's technology is based on an integrated pipeline: The system is implemented as:
Software-as-a-Medical-Device (SaMD)
Compliant with ISO 13485 and IEC 62304 standards

Scientific development

The development of the platform has been carried out progressively through:

  • In vitro models of decidualisation
  • Animal models
  • Endometrial transcriptomic studies
  • Multi-omics analyses
  • Validation through liquid biopsy

This approach has made it possible to establish a direct relationship between:
biological origin → molecular signal → detection in blood

Projects funded through competitive calls

iPremom takes part in projects funded through competitive calls, which support the scientific and technological development of our solutions.

logo generalitat valenciana, ivace, financiado por la unión europea y fondos europeos

Access the full scientific evidence

Consult publications, clinical studies and model validations.